trending Market Intelligence /marketintelligence/en/news-insights/trending/_VmYhvb8GCQpIhAmCmssbA2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

TBG Diagnostics to acquire China-based laboratory testing services company


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

TBG Diagnostics to acquire China-based laboratory testing services company

TBG Diagnostics Ltd., through its China-based unit TBG Biotechnology Xiamen, is acquiring Zhangsha ZhangYe Medical Laboratory Corp., a medical laboratory testing services company.

Under the deal, Greenslopes, Australia-based TBG Diagnostics will transfer 42.1% of TBG Xiamen's shares to the founding shareholders of China-based Zhangsha ZhangYe.

TBG Diagnostics, formerly known as Progen Pharmaceuticals Ltd., develops and sells molecular diagnostics kits, assays, instruments, and services in Taiwan, China and the U.S.

Dongyuan Huaxin (Beijing) Capital Management Co. Ltd., a Chinese private equity firm, will also buy 11.25% of TBG Xiamen's share capital for 10.7 million Chinese yuan in cash.

The proceeds will be reinvested in TBG Xiamen and will be used to expand the company's laboratories, diagnostic kits, sales capabilities and distribution channels.

As of Dec. 14, US$1 was equivalent to 6.91 Chinese yuan.